MEROPENEM | N215212 | HQ SPECIALTY PHARMA CORP
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 1 | Active | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | 39 | 2016-07 → 2026-12 | |
| Phase 4 | Recruiting | Rambam Health Care Campus | 1,084 | 2019-05-01 → 2027-04-01 | |
| Phase 2 | Completed | Pfizer | 83 | 2015-08-01 → 2017-06-01 | |
| Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2018-05-16 → 2022-02-16 | |
| Phase 2 | Completed | Pfizer | 204 | 2009-03-31 → 2009-12-31 | |
| Phase 3 | Completed | PENTA Foundation | 272 | 2012-09 → 2014-12 | |
| Phase 1/2 | Completed | Benazir Bhutto Hospital, Rawalpindi | 90 | 2013-01 → 2013-12 | |
| Phase 3 | Completed | Mansoura University | 100 | 2013-08 → 2015-06 | |
| Phase 1 | Completed | Hoffmann-La Roche | 46 | 2016-10-31 → 2017-03-24 | |
| Phase 3 | Completed | Merck Sharp & Dohme LLC | 268 | 2019-03-20 → 2020-10-14 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$119.53
Highest Price
$119.53
FSS NDCs
1
Big4 NDCs
0
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 44567-0402-06MEROPENEM 2GM/VIL INJ | $119.53 | FSS | WG Critical Care, LLC | 06/14/2029 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
10 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Dec 4, 2024 | SUPPL -2 | View Letter (PDF) |
| Jul 28, 2023 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.